COVID Vaccine Patent Fight Could Shift Costs
The ruling could affect future prices and availability of federally contracted vaccines like Spikevax.
Updated on Nov. 5, 2026 in COVID-19
Live Poll
Should drug companies be shielded from patent lawsuits over government-ordered vaccines?
A Federal Circuit panel heard arguments on whether Moderna is shielded from patent claims by Arbutus and Genevant over its COVID-19 vaccine Spikevax. The dispute centers on Moderna's argument that the U.S. government, which funded the vaccine through Operation Warp Speed, should be the defendant instead.
Why it matters
The outcome could determine whether companies that manufacture vaccines under federal contracts face patent liability, a question that affects the cost and supply of COVID-19 vaccines for Americans. Moderna's defense invokes a World War One-era law that protects patent claims that would interfere with supplying war materials, and the case would have been the first COVID vaccine patent dispute to reach trial.
The case rests on court rulings and a settlement agreement rather than clinical data. U.S. District Judge Joshua Wolson rejected Moderna's defense in February, and the Federal Circuit panel has now heard the appeal.
The players
Moderna
A biotechnology company known for its mRNA-based COVID-19 vaccine Spikevax and its mRNA platform for other vaccines and therapies.
Arbutus Biopharma
A biopharmaceutical company focused on lipid nanoparticle delivery technology used in mRNA therapeutics.
Genevant Sciences
A drug-delivery company that develops lipid nanoparticle technology, co-plaintiff with Arbutus in the patent dispute.
U.S. Department of Justice
The federal agency that represents the government in litigation and supported Moderna's government-supplier position in the appeal.
Federal Circuit Court of Appeals
The appellate court that reviews patent cases and is deciding whether Moderna's government-supplier defense applies.
The details
Arbutus and Genevant sued Moderna in 2022, seeking a share of royalties from Spikevax. Moderna argues that because it manufactured the vaccine for the federal government under Operation Warp Speed, the United States should be the defendant, a position the Department of Justice supports. The Federal Circuit's ruling will determine whether that government-contractor shield applies.
Timeline
February 2026: District judge mostly rejected Moderna's government-supplier defense.
March 2026: Moderna and Arbutus/Genevant reached a settlement.
July 2026: Moderna paid $950 million to Arbutus and Genevant.
November 5, 2026: The Federal Circuit heard oral arguments on Moderna's defense.
Health Landscape
The dispute tests whether vaccine makers working under Operation Warp Speed contracts can be held liable for patent infringement or whether the federal government bears that exposure. A ruling either way will shape how future federally backed vaccine and drug programs are structured and priced.
If you are considering a COVID-19 vaccine, the outcome of this case does not change the vaccine's safety or effectiveness, but it could affect future costs and availability of vaccines made under federal contracts. It is worth discussing your vaccination plans and any questions about booster timing with your doctor.
The takeaway
The case highlights how patent liability and federal contracting intersect for vaccines made during emergencies. Readers tracking vaccine access can watch for the Federal Circuit's ruling, and questions about your own vaccination schedule are best raised with your physician.
Further reading
For background on how the pandemic response shaped vaccine development, see our COVID-19 coverage.
Source note: This article includes information reported by Reuters.
Live Poll
Should drug companies be shielded from patent lawsuits over government-ordered vaccines?
